menu
    • menu
    [{"orgOrder":0,"company":"ANRS, Emerging Infectious Diseases","sponsor":"IRD, Epidemiology and Prevention, Montpellier, France | SESSTIM (IRD, Inserm, Universit\u00e9 Aix-Marseille) | Center for Research on Emerging and Re-Emerging Diseases | Facult\u00e9 de M\u00e9decine et des Sciences Biom\u00e9dicales, Universit\u00e9 de Yaound\u00e9 I, Yaound\u00e9, Camero","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Sofosbuvir","moa":"Hepatitis C virus NS5B RNA-dependent RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"ANRS, Emerging Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ANRS, Emerging Infectious Diseases \/ IRD, Epidemiology and Prevention, Montpellier, France | SESSTIM (IRD, Inserm, Universit\u00e9 Aix-Marseille) | Center for Research on Emerging and Re-Emerging Diseases | Facult\u00e9 de M\u00e9decine et des Sciences Biom\u00e9dicales, Universit\u00e9 de Yaound\u00e9 I, Yaound\u00e9, Camero","highestDevelopmentStatusID":"11","companyTruncated":"ANRS, Emerging Infectious Diseases \/ IRD, Epidemiology and Prevention, Montpellier, France | SESSTIM (IRD, Inserm, Universit\u00e9 Aix-Marseille) | Center for Research on Emerging and Re-Emerging Diseases | Facult\u00e9 de M\u00e9decine et des Sciences Biom\u00e9dicales, Universit\u00e9 de Yaound\u00e9 I, Yaound\u00e9, Camero"},{"orgOrder":0,"company":"AIDS Clinical Trials Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sofosbuvir","moa":"||Hepatitis C virus NS5B RNA-dependent RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"AIDS Clinical Trials Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AIDS Clinical Trials Group \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AIDS Clinical Trials Group \/ Undisclosed"},{"orgOrder":0,"company":"Columbia University","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sofosbuvir","moa":"Hepatitis C virus NS5B RNA-dependent RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Columbia University \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Columbia University \/ Undisclosed"},{"orgOrder":0,"company":"Catherine Anne Chappell","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sofosbuvir","moa":"Hepatitis C virus NS5B RNA-dependent RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Catherine Anne Chappell","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Catherine Anne Chappell \/ Gilead Sciences","highestDevelopmentStatusID":"11","companyTruncated":"Catherine Anne Chappell \/ Gilead Sciences"},{"orgOrder":0,"company":"Catherine Anne Chappell","sponsor":"Gilead Sciences | Gansu Provincial Maternal and Child Health Care Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sofosbuvir","moa":"Hepatitis C virus NS5B RNA-dependent RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Catherine Anne Chappell","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Catherine Anne Chappell \/ Gilead Sciences | Gansu Provincial Maternal and Child Health Care Hospital","highestDevelopmentStatusID":"11","companyTruncated":"Catherine Anne Chappell \/ Gilead Sciences | Gansu Provincial Maternal and Child Health Care Hospital"}]

    Find Clinical Drug Pipeline Developments & Deals for Sofosbuvir

    Menu

    Sofosbuvir

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AbbVie Inc

                            U.S.A
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sofosbuvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir a...

                            Details : Sofosbuvir is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hepatitis C.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 20, 2016

                            Lead Product(s) : Sofosbuvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ANRS, Emerging Infectious Diseases

                            Country arrow
                            Luxepack
                            Not Confirmed

                            ANRS, Emerging Infectious Diseases

                            Country arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sofosbuvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : IRD, Epidemiology and Prevention, Montpellier, France | SESSTIM (IRD, Inserm, Université Aix-Marseille) | Center for Research on Emerging and Re-Emerging Diseases | Faculté de Médecine et des Sciences Biomédicales, Université de Yaoundé I, Yaoundé, Camero

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Simplified vs Standard Test & Treat Strategy for Hepatitis C in Cameroon

                            Details : Sofosbuvir is a Other Small Molecule drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Hepatitis C.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 01, 2025

                            Lead Product(s) : Sofosbuvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : IRD, Epidemiology and Prevention, Montpellier, France | SESSTIM (IRD, Inserm, Université Aix-Marseille) | Center for Research on Emerging and Re-Emerging Diseases | Faculté de Médecine et des Sciences Biomédicales, Université de Yaoundé I, Yaoundé, Camero

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            AIDS Clinical Trials Group

                            Country arrow
                            Luxepack
                            Not Confirmed

                            AIDS Clinical Trials Group

                            Country arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sofosbuvir,Velpatasvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ACTG Announces Publication of Pivotal Hepatitis C Study in Clinical Infectious Diseases

                            Details : ACTG 5360 is a combination of sofosbuvir which is an inhibitor of the HCV NS5B RNA-dependent RNA polymerase, whereas velpatasvir is an inhibitor of the HCV NS5A protein, both required for viral replication. Currently being studied for chronic hepatitis C...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 23, 2023

                            Lead Product(s) : Sofosbuvir,Velpatasvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Catherine Anne Chappell

                            Country arrow
                            Luxepack
                            Not Confirmed

                            Catherine Anne Chappell

                            Country arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sofosbuvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Gilead Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy

                            Details : Sofosbuvir is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hepatitis C, Chronic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 02, 2021

                            Lead Product(s) : Sofosbuvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Gilead Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Columbia University

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            Columbia University

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sofosbuvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Researchers Identify Multiple Molecules tat Shut Down SARS-Cov-2 Polymerase Reaction

                            Details : Researchers at Columbia Engineering and the University of Wisconsin-Madison have identified a library of molecules that shut down the SARS-CoV-2 polymerase reaction. Five of these molecules are already FDA-approved for use in the treatment of other viral...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 30, 2020

                            Lead Product(s) : Sofosbuvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Catherine Anne Chappell

                            Country arrow
                            Luxepack
                            Not Confirmed

                            Catherine Anne Chappell

                            Country arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sofosbuvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Gilead Sciences | Gansu Provincial Maternal and Child Health Care Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Treatment of Chronic Hepatitis C During Pregnancy With Sofosbuvir/Velpatasvir

                            Details : Sofosbuvir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hepatitis C, Chronic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 11, 2020

                            Lead Product(s) : Sofosbuvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Gilead Sciences | Gansu Provincial Maternal and Child Health Care Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Gilead Sciences

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            Gilead Sciences

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sofosbuvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir (SOF/VEL) Fixed-Dose Combination (FDC) ...

                            Details : Sofosbuvir is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hepatitis C.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 26, 2019

                            Lead Product(s) : Sofosbuvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Gilead Sciences

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            Gilead Sciences

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sofosbuvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in ...

                            Details : Sofosbuvir is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hepatitis C.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 02, 2019

                            Lead Product(s) : Sofosbuvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            University of Pennsylvania

                            Country arrow
                            Luxepack
                            Not Confirmed

                            University of Pennsylvania

                            Country arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sofosbuvir

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : Gilead Sciences | National Institute of Diabetes and Digestive and Kidney Diseases

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Trial of Transplanting Hepatitis C Kidneys Into Hepatitis C-Negative Kidney Recipients

                            Details : Sofosbuvir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Kidney Failure, Chronic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 03, 2019

                            Lead Product(s) : Sofosbuvir

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : Gilead Sciences | National Institute of Diabetes and Digestive and Kidney Diseases

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            University of California, San Francisco

                            Country arrow
                            Luxepack
                            Not Confirmed

                            University of California, San Francisco

                            Country arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sofosbuvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Gilead Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The No One Waits Study: Acceptability and Feasibility of Community-based Point-of-diagnosis HCV Treatment Stud...

                            Details : Sofosbuvir is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hepatitis C, Chronic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 17, 2019

                            Lead Product(s) : Sofosbuvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Gilead Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth